These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26100271)

  • 1. Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?
    Neagu MR; Reardon DA
    Immunotherapy; 2015; 7(6):603-6. PubMed ID: 26100271
    [No Abstract]   [Full Text] [Related]  

  • 2. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
    Swartz AM; Li QJ; Sampson JH
    Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
    Reardon DA; Desjardins A; Vredenburgh JJ; O'Rourke DM; Tran DD; Fink KL; Nabors LB; Li G; Bota DA; Lukas RV; Ashby LS; Duic JP; Mrugala MM; Cruickshank S; Vitale L; He Y; Green JA; Yellin MJ; Turner CD; Keler T; Davis TA; Sampson JH;
    Clin Cancer Res; 2020 Apr; 26(7):1586-1594. PubMed ID: 32034072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospect of rindopepimut in the treatment of glioblastoma.
    Elsamadicy AA; Chongsathidkiet P; Desai R; Woroniecka K; Farber SH; Fecci PE; Sampson JH
    Expert Opin Biol Ther; 2017 Apr; 17(4):507-513. PubMed ID: 28274144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
    Del Vecchio CA; Wong AJ
    Curr Opin Mol Ther; 2010 Dec; 12(6):741-54. PubMed ID: 21154166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
    Del Vecchio CA; Li G; Wong AJ
    Expert Rev Vaccines; 2012 Feb; 11(2):133-44. PubMed ID: 22309662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.
    Gatson NT; Weathers SP; de Groot JF
    CNS Oncol; 2016; 5(1):11-26. PubMed ID: 26670466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Peptide vaccination in glioblastoma].
    Terasaki M; Morioka M
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):725-9. PubMed ID: 25167577
    [No Abstract]   [Full Text] [Related]  

  • 9. The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas.
    Li G; Mitra S; Wong AJ
    Neurosurg Clin N Am; 2010 Jan; 21(1):87-93. PubMed ID: 19944969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
    Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
    Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agenus cancer vaccine extends survival of GBM patients.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(2):252-3. PubMed ID: 24963517
    [No Abstract]   [Full Text] [Related]  

  • 12. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
    Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Peptide-based vaccine therapy for cancer patients].
    Yamada A
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():602-7. PubMed ID: 15861717
    [No Abstract]   [Full Text] [Related]  

  • 14. [Current status and prospects of cancer vaccine therapy].
    Mine T; Terazaki Y; Itoh K
    Nihon Rinsho; 2011 Sep; 69(9):1651-6. PubMed ID: 21922769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma.
    Hawkins-Daarud A; Rockne R; Corwin D; Anderson AR; Kinahan P; Swanson KR
    J R Soc Interface; 2015 Aug; 12(109):20150388. PubMed ID: 26202682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [II. Autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma].
    Maruyama T; Muragaki Y; Ishikawa E; Nitta M; Saito T; Ohno T; Iseki H; Okada Y
    Gan To Kagaku Ryoho; 2015 Jun; 42(6):683-6. PubMed ID: 26242005
    [No Abstract]   [Full Text] [Related]  

  • 17. [II.Current status of peptide vaccine for lung cancer].
    Suzuki H
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):1009- 14. PubMed ID: 24151657
    [No Abstract]   [Full Text] [Related]  

  • 18. ACT IV: the final act for rindopepimut?
    Gerstner ER
    Lancet Oncol; 2017 Oct; 18(10):1294-1296. PubMed ID: 28844498
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccine for aggressive brain tumors may prolong survival.
    Health News; 2004 Dec; 10(12):7. PubMed ID: 15645564
    [No Abstract]   [Full Text] [Related]  

  • 20. [Peptide vaccine treatment for colorectal cancer].
    Okuno K
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():574-8. PubMed ID: 22214026
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.